Disc Medicine, Inc. (IRON)

Compare

46.83

-1.70

(-3.50%)

As of 12:48:21 PM EDT. Market Open.

Is Disc Medicine, Inc. (NASDAQ:IRON) the Best Small Cap Stock to Buy Before They Explode?

We recently published a list of 10 Best Small-Cap Stocks to Buy Before They Explode. In this article, we are going to take a look at where Disc Medicine, Inc. (NASDAQ:IRON) stands against other best small-cap stocks to buy before they explode. Is Market Volatility Good For Small-Cap Stocks? Since the announcement of tariffs, investors […]

Insider Monkey 7 days ago

IRON
-3.50%
With 65% ownership, Disc Medicine, Inc. (NASDAQ:IRON) boasts of strong institutional backing

Key Insights Given the large stake in the stock by institutions, Disc Medicine's stock price might be vulnerable to...

Simply Wall St. 11 days ago

IRON
-3.50%
Victoria’s Secret, Bitdeer, and More Stocks See Activist Action

13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities.

Barrons.com 12 days ago

AQN

IRON
-3.50%
INVA
All You Need to Know About Disc Medicine, Inc. (IRON) Rating Upgrade to Buy

Disc Medicine, Inc. (IRON) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 20 days ago

IRON
-3.50%
Wall Street Analysts Predict a 68.78% Upside in Disc Medicine, Inc. (IRON): Here's What You Should Know

The consensus price target hints at a 68.8% upside potential for Disc Medicine, Inc. (IRON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks last month

IRON
-3.50%
Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Targeting NDA submission for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025 through accelerated approval pathway; on track to initiate APOLLO post-marketing confirmatory trial by mid-2025Positive update from Phase 1b trial of DISC-0974 in patients with anemia of myelofibrosis (MF) presented at ASH 2024; initial data from ongoing Phase 2 expected in H2 2025Positive data from initial cohorts of ongoing Phase 1b study of DISC-0974 in patients with anemia of non-dialysis-dependent chro

GlobeNewswire last month

IRON
-3.50%
Disc Medicine to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will present at three upcoming investor conferences: TD Cowen 45th Annual Health Care Conference (Boston, MA): Corporate presentation on Wednesday, March 5th at 9:10 a.m. ET.Leerink Global He

GlobeNewswire last month

IRON
-3.50%
Disc Medicine, Inc. (IRON) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Disc Medicine, Inc. (IRON) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks last month

IRON
-3.50%
Disc raises $225.5m as it eyes approval of rare skin disorder drug

Disc Medicine finalised the pivotal Phase III trial design of bitopertin in erythropoietic protoporphyria (EPP) with the FDA earlier this week.

Pharmaceutical Technology 2 months ago

IRON
-3.50%
Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

WATERTOWN, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the pricing of its upsized underwritten offering of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. Di

GlobeNewswire 2 months ago

IRON
-3.50%
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

WATERTOWN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it has commenced an underwritten offering of $200.0 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its

GlobeNewswire 2 months ago

IRON
-3.50%
Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission

Pursuing accelerated approval for bitopertin in EPP with protoporphyrin IX (PPIX) reduction as the surrogate endpointPlanning to submit NDA under accelerated approval pathway in H2 2025 based on existing clinical data, including results from BEACON and AURORA Phase 2 trialsAchieved regulatory alignment on APOLLO post-marketing confirmatory trial design and on track to initiate trial by mid-year 2025Aligned on average monthly time in light without pain during the last month of the 6-month treatme

GlobeNewswire 2 months ago

IRON
-3.50%
Disc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)

WATERTOWN, Mass., Jan. 20, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, will host a conference call to discuss feedback received from its Type C meeting on bitopertin in EPP with the U.S. Food and Drug Administration (FDA). The conference call will be held on Tuesday, January 21, at 8:00 am EST. Confer

GlobeNewswire 2 months ago

IRON
-3.50%
Disc Medicine Reports Inducement Grant under Nasdaq Listing Rule 5635(C)(4)

WATERTOWN, Mass., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the grant of an inducement equity award to a new employee, effective January 16, 2025. The inducement award is comprised of (i) an option to purchase 35,000 shares of Disc’s common stock, at an exercise price equal

GlobeNewswire 2 months ago

IRON
-3.50%
Disc Medicine Highlights Recent Achievements Across Hematology Portfolio and Key Business Objectives and Milestones for 2025

In Q1 2025, the Company will discuss the plans for NDA submission under a potential accelerated approval path for bitopertin in erythropoietic protoporphyria (EPP), following a Type C meeting with FDA on confirmatory study designInitial data from an ongoing phase 2 study of DISC-0974 (anti-hemojuvelin antibody) in anemia of myelofibrosis (MF) expected H2 2025 Data from higher doses and multiple dose cohorts of a phase 1b study of DISC-0974 in anemia of chronic kidney disease (CKD) expected H2 20

GlobeNewswire 2 months ago

IRON
-3.50%
An Intrinsic Calculation For Disc Medicine, Inc. (NASDAQ:IRON) Suggests It's 29% Undervalued

Key Insights Using the 2 Stage Free Cash Flow to Equity, Disc Medicine fair value estimate is US$89.52 Disc Medicine's...

Simply Wall St. 2 months ago

IRON
-3.50%
Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting

Positive updates across all programs, including updates from ongoing clinical studies and new translational data in preclinical models supporting use in existing and additional indicationsManagement hosted a conference call during the ASH meeting on Sunday, December 8 discussing highlights of the presented data and next steps for the company WATERTOWN, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery,

GlobeNewswire 3 months ago

IRON
-3.50%
Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual Meeting

Demonstrated durable hematologic response across all patient subgroups, regardless of baseline transfusion status and concomitant JAK inhibitor therapyPhase 2 study in MF anemia has been initiated, enrolling a broad range of patient types WATERTOWN, Mass., Dec. 08, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic di

GlobeNewswire 3 months ago

IRON
-3.50%
Raymond James Predicts Up to ~440% Rally for These 2 ‘Strong Buy’ Stocks

Now that the election is behind us, market watchers are digging into what Trump’s victory could mean for the economy in the coming months. As the former and future President prepares to take office, certain economic trends have already become clear: inflation has been slowing throughout much of this year, and the Federal Reserve has adopted a lower-rate policy – both of which are likely to support economic growth. More importantly, Trump has signaled his intent to pursue a deregulatory economic

TipRanks 4 months ago

MURA

IRON
-3.50%
Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update

Completed a successful end of Phase 2 meeting with the FDA for bitopertin in erythropoietic protoporphyria (EPP), reaching alignment on all proposed study parameters with the potential for accelerated approval based on existing dataPresented proof-of-mechanism data for Phase 1b trial of DISC-0974 in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) and anemia at the American Society of Nephrology (ASN) Kidney Week 2024Eight posters and an oral presentation across all three cl

GlobeNewswire 4 months ago

IRON
-3.50%

Performance Overview

Return	IRON	S&P 500 (^GSPC)
YTD	-26.14%	-7.05%
1-Year	+53.54%	+4.90%
3-Year	+8.40%	+20.26%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Live

Disc Medicine, Inc. (IRON)

Is Disc Medicine, Inc. (NASDAQ:IRON) the Best Small Cap Stock to Buy Before They Explode?

With 65% ownership, Disc Medicine, Inc. (NASDAQ:IRON) boasts of strong institutional backing

Victoria’s Secret, Bitdeer, and More Stocks See Activist Action

All You Need to Know About Disc Medicine, Inc. (IRON) Rating Upgrade to Buy

Wall Street Analysts Predict a 68.78% Upside in Disc Medicine, Inc. (IRON): Here's What You Should Know

Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Disc Medicine to Participate in Upcoming Investor Conferences

Disc Medicine, Inc. (IRON) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Disc raises $225.5m as it eyes approval of rare skin disorder drug

Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission

Disc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)

Disc Medicine Reports Inducement Grant under Nasdaq Listing Rule 5635(C)(4)

Disc Medicine Highlights Recent Achievements Across Hematology Portfolio and Key Business Objectives and Milestones for 2025

An Intrinsic Calculation For Disc Medicine, Inc. (NASDAQ:IRON) Suggests It's 29% Undervalued

Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting

Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual Meeting

Raymond James Predicts Up to ~440% Rally for These 2 ‘Strong Buy’ Stocks

Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update

Performance Overview